CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Phase 2

Active, not recruiting

• Conditions: Gastric Adenocarcinoma
• Interventions: Drug: Chemotherapy plus sintilimab and bevacizumab

• Registration Number: NCT06667050
• Lead Sponsor: West China Hospital

Brief Summary

Neoadjuvant chemotherapy has been recommended by a series of treatment guidelines for the neoadjuvant treatment of locally advanced G/GEJ cancer. Although with clinical efficacy, the pCR and long-term survival rates are still unsatisfactory and perioperative treatment mode for locally advanced G/GEJ cancer still needs further optimization. In this study, we will explore the efficacy and safety of chemotherapy combined with sintilimab and bevacizumab biosimilar (IBI305) in the neoadjuvant treatment for locally advanced G/GEJ cancer.

Detailed Description

This is a prospective, multicenter, single-arm, phase II trial. A total of 58 patients will be enrolled. Eligible patients will be registered and receive three cycles of CAPOX plus sintilimab and bevacizumab biosimilar (IBI305) regimen. Radical D2 gastric cancer resection will be performed 6-8 weeks after the last administration of chemotherapy plus plus sintilimab and bevacizumab biosimilar (IBI305). The primary endpoint of the study is the pathological complete response (pCR) rate. Secondary endpoints include R0 resection rate, major pathological response (MPR), event-free survival (EFS), overall survival (OS) and safety profile of the neoadjuvant regimen.

Study Timeline

• Status Verified: 2024-10
• Study Start: 2024-10-10
• Study First Submitted: 2024-10-27
• Study First Submitted QC: 2024-10-30
• Last Update Submitted: 2024-10-30
• Study First Posted: 2024-10-31
• Last Update Posted: 2024-10-31
• Primary Completion: 2026-10-31
• Study Completion: 2027-10-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

1. Age 18-75 years.

2. Histologically or cytologically confirmed diagnosis of locally advanced G/GEJ adenocarcinoma (cT3N+/T4aNany M0) as assessed by exploratory laparoscopic surgery, ultrasonography and/or CT/MRI.

3. Resectable G/GEJ cancer, as judged by experienced surgeons.

4. There was no previous antitumor treatment.

5. The expected survival is more than 3 months.

6. ECOG PS≤1.

7. Adequate organ function including the following:

   1. Total bilirubin ≤1.5 times the upper limit of normal (ULN);
   2. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3×ULN;
   3. Alkaline phosphatase≤2.5×ULN (if the tumor invaded the liver, ≤3×ULN);
   4. Serum creatinine≤1.5×ULN;
   5. Serum amylase and lipase≤1.5×ULN;
   6. International standardized ratio (INR)/partial thromboplastin time (PTT)≤1.5×ULN;
   7. Platelet count ≥ 100,000 /mm3;
   8. Hemoglobin (Hb) ≥ 9 g/dL;
   9. Absolute neutrophil count (ANC) ≥ 1500/mm3;

8. Strict contraception.

9. Patients must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.

Exclusion Criteria

1. Undergoing other drug clinical trials or having participated in any drug clinical trials one month before enrollment.

2. Active autoimmune disease or history of refractory autoimmune disease.

3. Receiving corticosteroids (> 10mg/d prednisone or equivalent dose of steroids) or other systematic immunosuppression therapies within 14 days before enrollment, excluding the following therapies: steroid hormone replacement therapy (≤10mg/d); local steroid therapy; and short-term, prophylactic steroid therapy for preventing allergies or nausea and vomiting.

4. Active or clinically significant cardiac disease:

   1. Congestive heart failure > New York Heart Association (NYHA) class 2;
   2. Active coronary artery disease;
   3. Arrhythmias requiring treatment other than β-blockers or digoxin;
   4. Unstable angina (with angina symptoms at rest), new angina within 3 months before enrollment, or new myocardial infarction within 6 months before enrollment

5. Evidence or history of bleeding diathesis or coagulopathy.

6. Grade 3 bleeding events 4 weeks before enrollment.

7. Thromboembolism or arteriovenous events, such as cerebrovascular events (including transient ischemic attack), deep vein thrombosis or pulmonary embolism, occurred 6 months before enrollment.

8. Currently taking anticoagulants.

9. Gastrointestinal perforation, gastrointestinal obstruction, or uncontrollable diarrhea 6 months before enrollment.

10. Other tumors that have not been treated or exist at the same time, except carcinoma in situ of the cervix, treated basal cell carcinoma or superficial bladder tumor. If the tumor was cured and no evidence of disease was found for more than 3 years, the patient can be enrolled. All other tumors must be treated at least 3 years before enrollment.

11. Patients with pheochromocytoma.

12. Patients with a history of HIV infection or active hepatitis B/C.

13. Ongoing > level 2 infection.

14. Symptomatic brain metastasis or meningioma.

15. Unhealed wounds, ulcers or fractures.

16. Renal failure patients requiring blood or peritoneal dialysis.

17. Epileptic that needs medication.

18. Active, symptomatic interstitial pneumonia, pleural or ascites that causes dyspnea (dyspnea ≥ 2 grade).

19. History of organ transplantation (including corneal transplantation).

20. Allergic to research drugs or similar drugs, or suspected allergies.

21. Pregnant or lactating women.

22. Medical, psychological or social conditions can affect the recruitment of patients and evaluation of study results.

23. Other antitumor therapy (chemotherapy, radiotherapy, surgery, immunotherapy, biotherapy, chemoembolization) other than investigator drugs. Palliative external irradiation for non-target lesions is allowed.

24. Previously used oxaliplatin, capecitabine, ICIs and anti-angiogenesis drugs;

25. Major surgery 4 weeks before recruitment, open biopsy or major trauma surgery (excluding biliary stents, or percutaneous biliary drainage).

26. Treatment with antitumor Chinese herbal medicine.

27. History of allogeneic blood transfusion within 6 months.

28. Vaccination history within 4 weeks before enrollment.

29. The investigator believes that patients who are not suitable for the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
chemotherapy plus sintilimab and bevacizumab biosimilar	Chemotherapy plus sintilimab and bevacizumab	capecitabine: 100 mg/m2, Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; sintilimab: 200 mg, iv drip, d1, bevacizumab biosimilar (IBI305) 10mg /Kg, iv drip, d1, q3w.

Primary Outcome Measures

Name	Time	Method
pCR rate	6 months after the last subject participating in	defined as the absence of viable tumor cells assessed by histological evaluation criteria after neoadjuvant therapy

Secondary Outcome Measures

Name	Time	Method
MPR rate	6 months after the last subject participating in	defined as tumor residual cells ≤10% in the surgical specimen
R0 resection rate	6 months after the last subject participating in	defined as the rate of the complete surgical removal of any residual cancer cells in the tumor bed
Event-free survival	2 years after the last subject participating in	defined as the time from randomization to occurrence of a major adverse clinical event, such as failure to achieve remission, relapse, and death during remission.
Overall survival	2 years after the last subject participating in	defined as the time from randomization to occurrence of death during remission.
Treatment-related adverse events	3 months after the last administration of drugs	Treatment-related adverse events as assessed by CTCAE v5.0

Trial Locations

Locations (1)

West China Hospital, Sichuan University; 🇨🇳 Chengdu, Sichuan, China